Chronic d-amphetamine induces sexually dimorphic effects on locomotion, recognition memory, and brain monoamines

• Published in: Pharmacology, biochemistry and behavior biochemistry and behavior, 2003-03, Vol.74 (4), p.859-867
• Main Authors: Bisagno, Veronica, Ferguson, Deveroux, Luine, Victoria N
• Format: Article
• Language: English
• Subjects: Animal; Animals; Biogenic Monoamines - metabolism; Biological and medical sciences; Brain - drug effects; Brain - metabolism; d-Amphetamine; Dextroamphetamine - administration & dosage; Female; Fundamental and applied biological sciences. Psychology; Learning. Memory; Male; Memory; Motor Activity - drug effects; Motor Activity - physiology; Psychology. Psychoanalysis. Psychiatry; Psychology. Psychophysiology; Rats; Rats, Sprague-Dawley; Recognition (Psychology) - drug effects; Recognition (Psychology) - physiology; Recognition memory; Sex Characteristics; Sexually dimorphic effects
• ISSN: 0091-3057; 1873-5177
• DOI: 10.1016/S0091-3057(03)00017-0

While acute and chronic d-amphetamine (AMPH) treatments produce greater scores for locomotor activity in female rats in comparison with male rats, little is known about AMPH-induced gender differences on cognition. The objectives of the present study were to (1) investigate during a withdrawal period following chronic AMPH treatment whether performance of two memory tasks, object recognition (OR) and object placement (OP) are altered, and (2) determine if an AMPH challenge dose after a withdrawal period amplifies previously reported gender differences in locomotor activity and neurochemistry. Sprague–Dawley male and female adult rats were included in a chronic AMPH treatment (10 injections, 1 every other day; males: 3 mg/kg, females 2.6 mg/kg). Locomotor activity was quantified (acute, chronic, and after a 16-day withdrawal period). Neurotransmitter levels in brain areas were evaluated after an AMPH challenge dose on the 16th withdrawal day. During the withdrawal period, OR (2- and 4-h delays) was impaired in AMPH-treated males but they did not show any impairment in OP; AMPH females also showed impairments in OR (only 4-h delay). AMPH females showed more locomotion after acute and chronic treatment but AMPH-induced hyperactivity was comparable for females and males after a challenge dose. Following a challenge dose of AMPH after a withdrawal period, gender differences in dopaminergic and serotonergic neurotransmission in the striatum were found. These gender differences elicited by AMPH in monoaminergic pathways may be related to sex differences on behavioral components involved in locomotion and OR memory.